ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
TGFBI Maintains Fibrocartilage Homeostasis by Restraining O-GlcNAcylation to Inactivate and Destabilize ADAMTS16 in Temporomandibular Joint Osteoarthritis.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The mandibular condyle is covered by fibrocartilage, and its degeneration, termed temporomandibular joint osteoarthritis (TMJOA), currently lacks effective disease-modifying therapies. In this study, we uncover a previously unrecognized mechanism by which the extracellular matrix protein TGFBI (TGF-β-induced) sustains condylar fibrocartilage homeostasis by restraining protein O-GlcNAcylation. We demonstrate that TGFBI is predominantly expressed in the condylar perichondrium and is markedly downregulated in both TMJOA patients and corresponding mouse models. Genetic ablation of Tgfbi delays postnatal skeletal development, promotes chondrocyte hypertrophy, and accelerates fibrocartilage degeneration. Mechanistically, TGFBI functions as a negative regulator of O-GlcNAcylation in condylar perichondrial cells (cPCs), thereby suppressing both the transcriptional activation and protein stability of the matrix protease ADAMTS16. Notably, ex vivo studies identify Ser1170 of ADAMTS16 as a critical O-GlcNAcylation site that directly governs its protein turnover. By inhibiting O-GlcNAcylation at this residue, TGFBI prevents condylar chondrocyte hypertrophy, senescence, and extracellular matrix degradation. Collectively, our findings establish the TGFBI-O-GlcNAcylation-ADAMTS16 axis as a vital driver of condylar fibrocartilage degeneration and highlight a promising metabolic target for TMJOA therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.